Table 1.
Sensitivity and specificity of markers in DNAs from NPC samples (n = 44) and non-cancerous controls (n = 18) from Morocco using MSP
| Marker gene | Sensitivity %a | Specificity %b |
|---|---|---|
| EBNA1 | 82 (36/44) | 94 (17/18) |
| U-LMP1 | 59 (26/44) | 94 (17/18) |
| M-RASSF1A | 66 (29/44) | 94 (17/18) |
| M-DAPK | 25 (11/44) | 72 (13/18) |
| M-ITGA9 | 50 (22/44) | 100 (18/18) |
| M-P16 | 45 (20/44) | 100 (18/18) |
| M-WNT7A | 69 (11/16) | 80 (4/5) |
| M-CHFR | 40 (16/40) | 67 (4/6) |
| M-CYB5R2 | 47 (17/36) | 75 (6/8) |
| M-WIF1 | 100 (10/10) | 25 (2/8) |
| M-RIZ1 | 0 (0/4) | 100 (3/3) |
| M-FSTL1 | 57 (4/7) | 67 (6/9) |
aSensitivity = number of positive cases in NPC patients/total number of NPC cases tested
bSpecificity = (total number of tested non-cancerous controls − number of positive cases in tested non-cancerous controls)/total number of tested non-cancerous controls